Europe may delay transparency

Share this article:

The push for clinical trial transparency may be delayed. Pharmalot reports that the European Medicines Agency is wading through more than 1,000 comments supporting the initiative and vociferous attacks from the industry and its backers who claim the initiative will threaten patient safety and corporate intellectual property. Threats to pack up and take jobs elsewhere have also accompanied industry concerns.

The EMA planned on having data out in the open by January 2104. It will decide in December if this date is still possible.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.